Retevmo in brazil?

Retevmo (lenzilumab) in Brazil

- Current status
As of the latest information available, Retevmo is **not yet approved by the Brazilian regulatory agency ANVISA** (Agência Nacional de Vigilância Sanitária). It has not entered the public market and is not listed among the drugs that can be prescribed or dispensed in Brazil.

- Why it’s not available
- Approval process: Every new therapeutic agent must undergo a formal registration process with ANVISA, including dossier submission, clinical data review, and sometimes post‑marketing surveillance agreements.
- Clinical evidence: Retevmo was granted Emergency Use Authorization (EUA) in the United States for treatment of severe COVID‑19, but it has not been studied extensively in Brazilian populations nor submitted for full approval there.
- Supply chain: Even if approved, distribution would require agreements with local manufacturers or importers, which are not yet in place.

- What you can do if you’re interested
1. Check ANVISA’s website – search their “Medicamentos” database for any updates on registration status.
2. Consult a healthcare professional – a physician or pharmacist familiar with infectious‑disease therapeutics can advise on alternative approved options for severe COVID‑19 or other indications.
3. Look for clinical trials – Retevmo may be available only through controlled studies. Sites such as clinicaltrials.gov or the Brazilian National Register of Clinical Trials (ReBEC) can list ongoing investigations.
4. Stay informed – drug approvals can change rapidly; keeping an eye on official announcements or reputable medical news outlets is a good practice.

- Alternatives in Brazil
For severe COVID‑19, Brazil has authorized a few monoclonal antibodies (e.g., REGN-COV2, bamlanivimab/etesevimab, and others) depending on the variant and timing. Vaccines, corticosteroids, and supportive care remain the mainstays of therapy.

---

Bottom line

Retevmo (lenzilumab) is not currently approved or available for prescription in Brazil. If you’re looking for effective COVID‑19 treatments or other indications, speak with a qualified medical professional and check the latest ANVISA guidelines.